secwatch.observer — SEC 8-K summary
======================================

Issuer:     Indivior Pharmaceuticals, Inc. (INDV)
CIK:        0001625297
Form:       8-K
Filed at:   2026-03-13T23:59:59+00:00
Accession:  0001625297-26-000012
Event type: debt
Sentiment:  neutral
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Indivior prices upsized $450M convertible notes at 0.625% due 2031
------------------------------------------------------------------

- Principal amount $450M (upsized from $400M); 0.625% interest, matures March 15, 2031.
- Net proceeds ~$437.7M (~$486.4M if initial purchasers' option fully exercised).
- ~$239M of proceeds plus $102M cash used to repay term loan and revolver.
- Concurrent $75M repurchase of ~2.4M shares from note purchasers at market price.
- Initial conversion price ~$41.66/share, a 35% premium over March 12 closing price.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1625297/000162529726000012/0001625297-26-000012-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1625297/000162529726000012/indv-20260312.htm
  HTML page:      https://secwatch.observer/filing/0001625297-26-000012

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer